Lung CancerNCT07701733
A Study of Lung Cancer Risk
An observational study of Lung Cancer, run by Memorial Sloan Kettering Cancer Center at 7 sites in United States.
Trial summary
The researchers are doing this study to learn more about factors that may increase the risk of lung cancer in people who have never smoked. This information may help predict which people who have never smoked may be more likely to get lung cancer. Read more about this study
- Who is it for?
- Ages 40 to 74 yearsHealthy volunteers can take part
- Conditions the study is for
- Lung Cancer
- What is being tested?
- Questionnaire
- How many people
- 500 participants
- Where
- 7 sitesUnited States
- Study dates
- 30 Jun 2026to Jun 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 74 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Case patients will be recruited from MSK Thoracic Surgery, Medical Oncology, and Radiation Oncology clinics. Case controls, frequency-matched for race (Asian, Black, Others, White) and age (40-49, 50-64, 65-74), will be recruited from among the 20,000 healthy women at average risk for whom screening mammography is performed annually at MSK and among women who present to the MSK Mobile Health Unit or Ralph Lauren Center for screening. The study will also be open to interested community members who meet eligibility criteria, identified through MSK Direct, the MSK Mobile Health Unit, MSK-Medisys partnership and other community outreach, including a community-facing website.
Criteria:
- Female at birth
- Age 40-74 years
- No smoking history
- Participants must be never-smokers, defined as having smoked <100 cigarettes in their lifetime
- Documentation of disease - case patients
- Case patients must have pathologically confirmed primary lung adenocarcinoma. New and prevalent cases will be eligible. Case patients with a history of prior non-lung cancer will be eligible for the study unless actively being diagnosed or treated for another form of cancer at the time of enrollment.
- Criteria for control participants
- Control participants must have no personal history of lung cancer, symptoms suspicious for lung cancer, or suspicious pulmonary nodules. Participants recruited as controls and found on imaging to have lesions suspicious for lung cancer will be excluded from analysis and followed prospectively. Data regarding these participants will be reported in a sensitivity analysis. Additional control participants will be recruited to ensure balanced age- and race-matched enrollment by frequency matching. Control participants with a history of prior non-lung cancer will be eligible for the study unless actively being diagnosed or treated for another form of cancer at the time of enrollment.
Trial locations and contacts
7 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Tafadzwa Chaunzwa, MD contact
7 sites in 1 country
United States7 sites, 7 recruiting
- Recruiting
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, New Jersey, 07920
Alexis Chidi, MD, PhD, 929-829-0677
- Recruiting
Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)
Commack, New York, 11725
Alexis Chidi, MD, PhD, 929-829-0677
- Recruiting
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York, 10604
Alexis Chidi, MD, PhD, 929-829-0677
- Recruiting
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, New Jersey, 07748
Alexis Chidi, MD, PhD, 929-829-0677
- Recruiting
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale, New Jersey, 07645
Alexis Chidi, MD, PhD, 929-829-0677
- Recruiting
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065
Alexis Chidi, MD, PhD, 929-829-0677
- Recruiting
Memorial Sloan Kettering Nassau (All Protocol Activities)
Uniondale, New York, 11553
Alexis Chidi, MD, PhD, 929-829-0677
About this study
Official title: ARISE: Assessing Lung Cancer Risk in Never-Smoking Women
The researchers are doing this study to learn more about factors that may increase the risk of lung cancer in people who have never smoked. This information may help predict which people who have never smoked may be more likely to get lung cancer.
- Conditions
- Lung Cancer
- Being tested
- Questionnaire
- Keywords
- 26-239
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QuestionnaireOther
The study questionnaire will be administered at a regular treatment visit for case patients and at a study-specific visit for control participants. At the same visit, 1 vial of blood will be collected for genomic analysis for research purposes from both case patients and control participants. Collection of demographic information and exposure data.
| Study group | Role | What they receive |
|---|---|---|
| Case patients | Must have pathologically confirmed primary lung adenocarcinoma. Receives: Other: Questionnaire | |
| Control participants | Must have no personal history of lung cancer, symptoms suspicious for lung cancer, or suspicious pulmonary nodules. Receives: Other: Questionnaire |
What is being measured
The primary outcome is the main question the study is designed to answer.
Identify factors associated with the risk of NSCLC
analyses will include all participants who completed the demographic and exposure assessment and whole-exome sequencing
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2026
- Study start30 Jun 2026
- Primary completionJun 2029 (estimated)
- Study completionJun 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- More trials run by Memorial Sloan Kettering Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Alexis Chidi, MD, PhD, Principal investigator, Memorial Sloan Kettering Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07701733
- Sponsor's protocol ID
- 26-239
- Status last verified
- Aug 2026
- First submitted
- 1 Jul 2026
- Last updated
- 14 Aug 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- ARISE: Assessing Lung Cancer Risk in Never-Smoking Women
- ClinicalTrials.gov ID
- NCT07701733
- Acronym / sponsor ID
- 26-239
- Conditions
- Lung Cancer
- Keywords
- 26-239
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterUniversity, hospital or other
- Study start
- 30 Jun 2026 (actual)
- Primary completion
- Jun 2029 (estimated)
- Study completion
- Jun 2029 (estimated)
- First posted
- 14 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The researchers are doing this study to learn more about factors that may increase the risk of lung cancer in people who have never smoked. This information may help predict which people who have never smoked may be more likely to get lung cancer.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Case patients | – | Other: QuestionnaireMust have pathologically confirmed primary lung adenocarcinoma. |
| Control participants | – | Other: QuestionnaireMust have no personal history of lung cancer, symptoms suspicious for lung cancer, or suspicious pulmonary nodules. |
Who may qualify
- Ages
- 40 to 74 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Case patients will be recruited from MSK Thoracic Surgery, Medical Oncology, and Radiation Oncology clinics. Case controls, frequency-matched for race (Asian, Black, Others, White) and age (40-49, 50-64, 65-74), will be recruited from among the 20,000 healthy women at average risk for whom screening mammography is performed annually at MSK and among women who present to the MSK Mobile Health Unit or Ralph Lauren Center for screening. The study will also be open to interested community members who meet eligibility criteria, identified through MSK Direct, the MSK Mobile Health Unit, MSK-Medisys partnership and other community outreach, including a community-facing website.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| QuestionnaireThe study questionnaire will be administered at a regular treatment visit for case patients and at a study-specific visit for control participants. At the same visit, 1 vial of blood will be collected for genomic analysis for research purposes from both case patients and control participants. Collection of demographic information and exposure data. | Other | Case patients, Control participants |
Primary outcome
Identify factors associated with the risk of NSCLC
Time frame: 3 years
analyses will include all participants who completed the demographic and exposure assessment and whole-exome sequencing
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2026.
- Memorial Sloan Kettering Cancer CenterLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Related trials for Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Tafadzwa Chaunzwa, MD contact
Alexis Chidi, MD, PhD principal investigator
Memorial Sloan Kettering Cancer Center
7 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Cancer, run by Memorial Sloan Kettering Cancer Center at 7 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Alexis Chidi, MD, PhD ((929) 829-0677, arisestudy@mskcc.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Identify factors associated with the risk of NSCLC (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2026.